Ahead of its obesity launch, Lilly's retatrutide is creeping closer to market for sleep apnea.
endpoints.newsLilly’s retatrutide creeps closer to market for sleep apneaLilly’s triple agonist retatrutide cuts sleep apnea severity by up to 24.7 events/hr vs. placebo in two Phase 3 OSA sub-studies.
0 reposts0 likes